Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Psoriatic ArthritisRheumatoid ArthritisSpinal Disorders

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany

Rheumatol Int.

Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH

doi: 10.1007/s00296-018-4180-4.

COMMENTED

Psoriatic ArthritisSpinal Disorders

Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis

J Rheumatol.

Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, Porter B, Safi J Jr, Shete A, Bruin G

doi: 10.3899/jrheum.190116.

Psoriatic ArthritisRheumatoid Arthritis

Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study.

Rheumatol Int.

Nissen CB, Hørslev-Petersen K, Primdahl J

Psoriasis

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

JAMA Dermatol

Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, Soung J, Bao W, Keininger D, Marfo K, Patekar M, Sharma A, Shete A, Lebwohl MG

doi: 10.1001/jamadermatol.2020.3257

PsoriasisPsoriatic ArthritisSpinal Disorders

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

Ann Rheum Dis.

Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T

doi: 10.1136/annrheumdis-2018-214273.

Psoriasis

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data

Br J Dermatol

Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, Jehl V, Marfo K, Primatesta P, Shete A, Trivedi V, Mease PJ

doi: 10.1111/bjd.20136

Psoriatic ArthritisRheumatoid Arthritis

Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission

Clin Exp Rheumatol.

Ramírez J, Iniciarte-Mundo J, Cuervo A, Ruiz-Esquide V, Hernández MV, Sanmartí R, Cañete JD

Psoriatic ArthritisRheumatoid Arthritis

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Patient Prefer Adherence.

Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A

doi: 10.2147/PPA.S128665.

Psoriatic Arthritis

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Arthritis Res Ther.

Combe B, Rahman P, Kameda H, Cañete JD, Gallo G, Agada N, Xu W, Genovese MC

doi: 10.1186/s13075-020-2099-0.

Related content

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany

Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis

Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study.

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data

Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis